Welcome to our dedicated page for Mind Medicine news (Ticker: MNMD), a resource for investors and traders seeking the latest updates and insights on Mind Medicine stock.
Mind Medicine Inc. (MNMD) is a clinical-stage biotech company pioneering research into psychedelic-inspired therapies for mental health disorders. This dedicated news hub provides investors and researchers with timely updates on MNMD's scientific advancements, regulatory milestones, and strategic initiatives.
Access official press releases detailing clinical trial progress, partnership announcements with leading research institutions, and analyses of the company's novel approaches to treating conditions like addiction and depression. Our curated collection ensures you stay informed about MNMD's work developing therapies that target neuroplasticity through compounds such as LSD-analogs and psilocybin derivatives.
Key updates include Phase 2 trial results, intellectual property developments, executive leadership changes, and presentations at major medical conferences. All content is sourced from verified channels to maintain compliance with financial disclosure standards.
Bookmark this page for streamlined access to MNMD's evolving story in psychedelic medicine. Check regularly for critical updates about FDA-regulated research programs and breakthrough therapy designation tracking within this emerging biopharmaceutical sector.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced the publication of a study on the interaction between the SSRI escitalopram and psilocybin effects in healthy volunteers. Conducted by the University Hospital Basel, the study revealed that escitalopram did not significantly affect the positive mood effects of psilocybin but reduced negative outcomes like anxiety. The findings suggest that psilocybin can be administered without stopping escitalopram, paving the way for future research in clinical settings.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has initiated recruitment for a randomized placebo-controlled study to evaluate the effects of low-dose LSD on neuroplasticity and various cognitive measures. Conducted by Dr. Kim Kuypers from Maastricht University, the study aims to explore whether the timing of LSD administration influences its impact. The research focuses on measuring BDNF plasma levels, sleep, mood, cognitive performance, and immune response. This innovative study design combines digital and traditional methods to shed light on the potential benefits of microdosing psychedelics.
MindMed (NASDAQ: MNMD) reported its financial results for Q3 2021, showcasing a cash balance of $145.9 million as of September 30, 2021, up from $80.1 million at the end of 2020. However, the company faced a net loss of $24.3 million for the quarter, compared to $8.6 million in Q3 2020. Operating cash outflows rose significantly, amounting to $10.8 million in Q3 2021 versus $5.8 million in Q3 2020. The firm appointed new board members and expanded its scientific advisory board, enhancing its drug development efforts in psychedelic-inspired therapies.
On November 12, 2021, Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced that its CEO, Robert Barrow, will speak at the Jefferies 2021 London Healthcare Conference from November 16-19. The management team will be available for both in-person and virtual one-on-one meetings. A webcast of Barrow's presentation will be available on-demand starting November 17 at 9:20 AM GMT. MindMed is focused on developing psychedelic-inspired therapies for mental illness.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has appointed Dr. Maria A. Oquendo to its Scientific Advisory Board. Dr. Oquendo is the Ruth Meltzer Professor and Chairman of Psychiatry at the University of Pennsylvania, recognized for her extensive work in psychiatry and neuroimaging related to mood disorders and suicidality. Her appointment is expected to enhance MindMed’s efforts in developing psychedelic-inspired therapies. The company aims to offer innovative treatments for mental health and addiction issues while navigating industry challenges.
Mind Medicine (MindMed) has announced a new program to develop R(-)-MDMA aimed at treating social anxiety and improving functioning for conditions like Autism Spectrum Disorder (ASD). This initiative represents a significant expansion of MindMed's drug pipeline, addressing a substantial unmet medical need, particularly as ASD affects around 2% of the U.S. population. With no approved therapies targeting core ASD symptoms, the estimated economic cost of ASD in the U.S. is projected to reach $461 billion by 2025. Initial clinical trials for R(-)-MDMA are expected to begin in 2022.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced that Chief Medical Officer Daniel R. Karlin will chair The Digital Biomarkers & Digital Measurements Summit on October 26-27, 2021. Dr. Karlin emphasized the importance of bridging the gap between technological promises and real-world applications in healthcare. The summit aims to enhance understanding and collaboration in the realm of digital biomarkers and measurements, which are critical in pharmaceutical development. MindMed focuses on developing psychedelic-inspired therapies targeting addiction and mental health disorders.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has joined the Clinical Trials Transformation Initiative (CTTI) to enhance the quality and efficiency of clinical trials. As one of about 80 member organizations, MindMed aims to drive innovations in clinical research. The company, represented by its Chief Medical Officer, emphasizes its commitment to improving the clinical trial process and ensuring the accessibility of psychedelic therapies in mental healthcare. CTTI's vision, 'Transforming Trials 2030', focuses on patient-centered, quality trials integrated into health processes.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has partnered with Sphere Health to advance mental health research, specifically targeting anxiety and affective disorders. The collaboration seeks to utilize consumer technology to gather multimodal data for a new study, MM061302. This initiative aims to enhance machine learning tools for predicting symptoms of mental health conditions. The study will maintain patient privacy through de-identified data linked with Datavant. MindMed emphasizes the need for more research to improve treatment methodologies while ensuring ethical standards in clinical care.
Mind Medicine (MindMed) has appointed Andreas Krebs and Carol Vallone as directors, effective immediately. Krebs, an experienced executive and author, has a background in growth companies and leadership roles at major corporations. Vallone is known for her track record in launching and scaling companies and has held key positions in healthcare and education sectors. The appointments follow the departure of Bruce Linton, who contributed to the company's growth. Their addition aims to enhance MindMed's strategic direction in developing psychedelic-inspired therapies. Regulatory approval is pending.
